US 12,478,710 B2
Embolic compositions and methods
Jeffrey Groom, Belmont, MA (US); Craig Wiltsey, Waltham, MA (US); Quynh Pham, Methuen, MA (US); Nikhita Mansukhani, Allston, MA (US); Courtney Guertin, Watertown, MA (US); Lee Core, Needham, MA (US); and Upma Sharma, Somerville, MA (US)
Assigned to Arsenal Medical, Inc., Waltham, MA (US)
Appl. No. 18/001,024
Filed by Arsenal Medical, Inc., Watertown, MA (US)
PCT Filed Jun. 9, 2021, PCT No. PCT/US2021/036636
§ 371(c)(1), (2) Date Dec. 7, 2022,
PCT Pub. No. WO2021/252642, PCT Pub. Date Dec. 16, 2021.
Prior Publication US 2023/0218798 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61L 24/06 (2006.01); A61K 47/02 (2006.01); A61K 47/34 (2017.01); A61K 49/04 (2006.01); A61L 24/00 (2006.01); A61L 24/02 (2006.01); A61L 24/04 (2006.01); C08L 83/04 (2006.01)
CPC A61L 24/06 (2013.01) [A61K 47/02 (2013.01); A61K 47/34 (2013.01); A61K 49/04 (2013.01); A61K 49/0409 (2013.01); A61L 24/0021 (2013.01); A61L 24/02 (2013.01); A61L 24/043 (2013.01); A61L 24/046 (2013.01); C08L 83/04 (2013.01); A61L 2400/06 (2013.01); A61L 2430/36 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A kit comprising (a) a first fluid composition that comprises a first polysiloxane having two or more unsaturated groups, a first silica filler, and a first imaging agent, (b) a second fluid composition that comprises a first hydride material having two or more hydride groups, a second silica filler, and a second imaging agent and (c) one or more components for mixing and delivery of the first fluid composition and the second fluid composition, wherein at least one of said first and second fluid compositions comprises a catalyst for catalyzing a reaction between the unsaturated groups and the hydride groups, wherein the first and second silica fillers may be the same or different, wherein the first and second imaging agents may be the same or different, and wherein the first fluid composition and the second fluid composition, when mixed, form a crosslinkable composition, wherein the first and second imaging agents each comprise bismuth trioxide.